



## PRESS RELEASE

Axxam and the Neurodegeneration Consortium at The University of Texas MD Anderson Cancer Center collaborate on a novel approach to Alzheimer's disease research

**December 4<sup>th</sup>, 2015 – Axxam SpA (Milan/Italy)** announced today that it has entered into a research collaboration with the Neurodegeneration Consortium (NDC) at The University of Texas MD Anderson Cancer Center (MD Anderson). The aim of the collaboration is to identify and develop novel small molecule modulators of an undisclosed G-protein coupled receptor linked to Alzheimer's disease.

This collaboration is the latest addition to a multi-year relationship between Axxam and MD Anderson and builds on Axxam's expertise in the development of robust functional assays for membrane proteins, its screening platform, the access to Axxam's compound collection AXX<sup>DIV2.0</sup> and the significant experience at both Axxam and MD Anderson of integrated neuroscience drug discovery.

Stefan Lohmer, co-founder and Chief Executive Officer at Axxam, commented: "We at Axxam are very happy to be opening this new chapter in our collaboration with our colleagues at MD Anderson, sharing our experience and platforms with such a world-class research organization in order to set the ground for new Alzheimer's disease therapies".

***For more information about Axxam, or to speak with Dr. Lohmer, please contact Sabrina Corazza at +39 02 2105634 or [sabrina.corazza.sc@axxam.com](mailto:sabrina.corazza.sc@axxam.com).***

***About Axxam SpA ([www.axxam.com](http://www.axxam.com))***

*Axxam SpA is a privately owned contract research and discovery company located at the Science Park Openzone in Bresso (Milan, Italy). The Company is a leading provider of integrated discovery services for the entire Life Sciences industries as: Pharmaceutical, Crop protection, Animal health, Cosmetics and Nutrition. Axxam has a strong expertise across a broad range of discovery disciplines and innovative technologies, including: assay development, compound management, HTS, hit identification and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need.*